Get the Stockscreener App
4.52
1.09%
-0.05
Agenus Inc stock is traded at $4.52, with a volume of 392.07K.
It is down -1.09% in the last 24 hours and down -26.14% over the past month.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
See More
Previous Close:
$4.57
Open:
$4.6
24h Volume:
392.07K
Relative Volume:
0.33
Market Cap:
$144.03M
Revenue:
$160.43M
Net Income/Loss:
$-227.64M
P/E Ratio:
-0.0657
EPS:
-68.77
Net Cash Flow:
$-170.79M
1W Performance:
-2.38%
1M Performance:
-26.14%
6M Performance:
+36.14%
1Y Performance:
-17.37%
1-Day Range:
$4.49
$4.70
1-Week Range:
$4.36
$4.70
52-Week Range:
$1.38
$7.34
Agenus Inc Stock (AGEN) Company Profile
Name
Agenus Inc
Sector
Industry
Phone
781-674-4410
Address
3 FORBES ROAD, LEXINGTON, MA
Compare AGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
4.52 | 144.34M | 160.43M | -227.64M | -170.79M | -68.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-04-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-19-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-18-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-18-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-06-23 | Initiated | Robert W. Baird | Outperform |
| Feb-28-23 | Resumed | H.C. Wainwright | Buy |
| Sep-28-22 | Initiated | SMBC Nikko | Outperform |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Apr-22-19 | Initiated | B. Riley FBR | Buy |
| Oct-28-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-27-16 | Reiterated | Maxim Group | Buy |
| Mar-11-16 | Upgrade | Maxim Group | Hold → Buy |
| Dec-16-15 | Initiated | Jefferies | Buy |
| Oct-27-15 | Downgrade | Maxim Group | Buy → Hold |
| Jul-27-15 | Reiterated | MLV & Co | Buy |
| Jun-11-15 | Initiated | Oppenheimer | Outperform |
| Jan-12-15 | Reiterated | Maxim Group | Buy |
| Jan-09-15 | Reiterated | MLV & Co | Buy |
| Jan-09-15 | Reiterated | Maxim Group | Buy |
| Dec-19-14 | Reiterated | Maxim Group | Buy |
| May-08-14 | Reiterated | Maxim Group | Buy |
| Mar-14-14 | Reiterated | MLV & Co | Buy |
| Oct-08-13 | Reiterated | Maxim Group | Buy |
| Jan-05-12 | Initiated | William Blair | Outperform |
| Dec-01-11 | Initiated | Global Hunter Securities | Buy |
View All
Agenus Inc Stock (AGEN) Latest News
Can Agenus Inc. Regain Lost Ground This QuarterJuly 2025 News Drivers & Breakout Confirmation Alerts - newsyoung.net
Agenus to host virtual stakeholder briefing on cancer treatment - Investing.com
Agenus to Unveil Strategic Advancements and Key Milestones in Virtual Stakeholder Briefing on August 27, 2025 - AInvest
Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025 - MarketScreener
Chartists Watching For Breakout in Agenus Inc.Quarterly Earnings Report & AI Enhanced Trading Alerts - beatles.ru
PD-(L)1 Inhibitors Market Set to Surge During the Forecast Period (2025–2034) as Immuno-Oncology Therapies Gain Momentum | DelveInsight - GlobeNewswire Inc.
Fibonacci Support Holding Strong in Agenus Inc.Earnings Risk Report & AI Powered Buy and Sell Recommendations - newsimpact.co.kr
Is Agenus Inc.’s ROIC above industry average2025 Key Lessons & Community Consensus Picks - classian.co.kr
Agenus Inc.’s Price Action Aligns with Quant SignalsM&A Rumor & Capital Efficiency Focused Strategies - sundaytimes.kr
Agenus Inc. Matches Institutional Buying FilterPortfolio Gains Report & High Conviction Buy Zone Picks - newsyoung.net
Agenus Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before November 5, 2024 to Discuss Your RightsAGEN - ACCESS Newswire
Agenus Inc. Reports Q2 2025 Financial Results - TipRanks
Agenus Inc. Faces Ongoing Risks: What Investors Need to Know - TipRanks
Agenus Inc Reports Q2 2025 Earnings: EPS Loss of $2.03, Revenue at $25.7 Million, Missing Estimates. - AInvest
Technical analysis overview for Agenus Inc. stockEarnings Recap Summary & AI Driven Stock Price Forecasts - Newser
Will breakout in Agenus Inc. lead to full recovery2025 Analyst Calls & Real-Time Chart Breakout Alerts - Newser
Key metrics from Agenus Inc.’s quarterly dataMarket Risk Summary & Free Low Drawdown Momentum Trade Ideas - Newser
Real time alert setup for Agenus Inc. performanceMarket Trend Review & Expert-Curated Trade Recommendations - Newser
Trapped Investors in Agenus Inc. Await Breakout SignalWeekly Stock Recap & Consistent Profit Alerts - sundaytimes.kr
Agenus Inc Reports Q2 2025 Earnings: EPS Loss of $2.03, Revenue at $25.7 Million, Missing Estimates - GuruFocus
Is Agenus Inc. still worth holding after the dipRecession Risk & AI Optimized Trade Strategies - Newser
Agenus Faces Ongoing Risks Despite Stable Consensus - AInvest
Can Agenus Inc. disrupt its industryMultiplier Stock Alert - thegnnews.com
Agenus Inc. shares rise 2.29% after-hours following Q2 earnings report. - AInvest
Agenus: Cash Starved Pharma Counting On Bot/Bal Cancer Bounty (NASDAQ:AGEN) - Seeking Alpha
Agenus Inc (AGEN) Stock: Exploring a Year of Highs, Lows, and Trading Volume - investchronicle.com
Agenus 2025 Q2 Earnings Improved Losses Amid Strategic Momentum - AInvest
Agenus Inc. shares fall 3.75% premarket after reporting a $30 million loss in Q2 earnings. - AInvest
Agenus Inc. stock trendline breakdownAI Trend Detection for Entry Timing - Newser
Agenus stock price target lowered to $23 by H.C. Wainwright on higher expenses - Investing.com Canada
Agenus: Q2 Earnings Snapshot - Stamford Advocate
Agenus (AGEN) Reports Q2 Loss, Beats Revenue Estimates - sharewise.com
Agenus Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Agenus Posts 48% Q2 Revenue Miss - AOL.com
Agenus Reports Q2 2025 Financials, Secures $91M, and Plans Phase 3 Trial for BOT/BAL Therapy. - AInvest
Agenus: A Contrarian Play on Immuno-Oncology's Next Frontier Amid Financial Reengineering - AInvest
Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress - The Globe and Mail
Smart tools for monitoring Agenus Inc.’s price actionTrading Watchlist with Real Time Filters - Newser
Is Agenus Inc. exposed to currency risksHigh Profit Stock Recommendations - kangso.co.kr
Agenus Earnings Outlook: Analysts Expect $0.50 EPS in Q2 2025 - AInvest
Agenus (AGEN) Expected to Announce Earnings on Monday - Defense World
Agenus (NASDAQ:AGEN) Upgraded to Buy at Wall Street Zen - Defense World
Agenus AGEN Q2 2025 Earnings Preview Upside Potential on Strategic CDMO Shift - AInvest
Examining the Future: Agenus's Earnings Outlook - 富途牛牛
Should value investors consider Agenus Inc.ROI Enhanced Trading Plan - newsyoung.net
Why Agenus Inc. stock attracts strong analyst attentionInsider Strategy for High Conviction Picks - Newser
Agenus Inc Stock (AGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):